OncoSil Medical (ASX:OSL) has appointed Dr Ashish Soman as its chief medical officer in the lead-up to commercialisation of its OncoSil™ localised radiation treatment for pancreatic and primary liver cancer.
He has over 24 years of experience and will play a key role in the upcoming regulatory approvals process, including European CE Mark and US FDA Investigational Device Exemption.
Dr Soman will be responsible for the development of a full Clinical Development program in support of OncoSil™, a key part of which will be the commercialisation of the OncoSil™, later in 2015.
His previous roles include country medical director, Australia for major bio-pharmaceutical company AstraZeneca from 2012-2014, where he managed a team of 30 employees spanning medical affairs, medical information and publications, compliance and patient safety.
Prior to that he was medical director - cardiovascular & diabetes for AstraZeneca Australia, from 2009-2012.
Dr Soman has also previously held roles with Sanofi-aventis Australia-New Zealand, from 2006-2009, and Roche Products Ltd in the UK, from 2004-2006.
“We are delighted to welcome Dr Soman to the OncoSil Medical team, and his is a key appointment as the company moves into the advanced stages of our regulatory approvals and commercialisation process for OncoSil™,” chief executive officer Daniel Kenny said.
“He is an experienced pharmaceutical physician and former country medical director with AstraZeneca and has broad therapy area knowledge including oncology.
“Dr Soman also has strong technical expertise in medical affairs, R&D, patient safety and medical compliance, and his diverse skill sets make him the ideal candidate to fulfil the role as chief medical officer.”
The company is on schedule for the Conformité Européenne (CE) Mark approval of OncoSil™ in the third quarter of 2015.
Commercialisation in the European Union would also facilitate sales in other major markets, with the global market for Pancreatic Cancer being US$1 billion, and for HCC Liver Cancer an additional US$1.4 billion.
OncoSil™
OncoSil™ is an implantable nuclear medicine (radiotherapy) device for the treatment of cancer, and is the company's lead product candidate.
It has been successfully piloted in pancreatic and liver cancer. It has clinically demonstrated target tumour regression (tumour shrinkage) in both solid tumour indications of pancreatic and liver cancer.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.